KOL Views: Getting an early read on the impact of Opdivo’s failure in front-line lung cancer

Last week saw the first major stumble by an anti-PD-(L)1 mAb when Opdivo (nivolumab) missed the primary endpoint of progression-free survival in a Phase III trial in non-small-cell lung cancer (NSCLC), causing investors to transfer billions of dollars in valuation from Bristol-Myers Squibb to Merck & Co, which is now in the driver’s seat to grab a dominant share of the single most lucrative oncology market with Keytruda (pembrolizumab). (See ViewPoints: Aggressive development strategy with Opdivo comes back to bite Bristol-Myers Squibb.)

To provide FirstWord readers with a better understanding of how the balance of power among PD-(L)1 inhibitors may change in light of the results, we are hosting an expert call with a leading key opinion leader on Wednesday (August 10).

Key topics that will be discussed during the call include, among other things… how the readout affects sentiment towards Opdivo, Keytruda and other anti-PD-(L)1 mAbs; what is the immediate impact on use of anti-PD-(L)1 mAbs as first- and second-line therapy for NSCLC; and how the new data could change attitudes towards PD-L1 testing and thresholds.

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to last week’s Opdivo results.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.